Preferential Hyperacuity Home Testing for Monitoring Intermediate Age-related Macular Degeneration in Routine Clinical Practice
Open Access
- 6 June 2020
- journal article
- Published by Scientific Scholar in American Journal of Ophthalmic Clinical Trials
Abstract
Objectives: A home monitoring device (ForeseeHome; Notal Vision, Tel Aviv, Israel) detected choroidal neovascularization in age-related macular degeneration (AMD) earlier than home and office monitoring. This study describes device usage in routine clinical practice. Materials and Methods: An Institutional Review Board-approved retrospective chart review of intermediate AMD patients who used the device at a single tertiary care center. Primary outcomes were duration and frequency of usage and outcomes of alerts generated. Results: Sixty-two patients (106 eyes) completed monitoring 4.2 ± 2.1 times per week (avg ± std dev) from February 2015 to February 2019. Forty-five eyes discontinued monitoring after an average of 65 days (range 13–237 days), due to poor quality tests (62%), and false-positive alerts (16%). Eyes that discontinued device monitoring were older and had poorer visual acuity than eyes that continued monitoring (P < 0.01). Fourteen alerts were generated, of which one represented conversion to exudative AMD. Two additional converted eyes were identified by routine office visit and Amsler grid monitoring. Conclusions: Home monitoring has the potential to improve the detection of exudative AMD. Identifying barriers to device utilization are necessary in the AMD population.Keywords
This publication has 17 references indexed in Scilit:
- Baseline Predictors for Five-Year Visual Acuity Outcomes in the Comparison of AMD Treatment TrialsOphthalmology Retina, 2018
- Incidence of Late-Stage Age-Related Macular Degeneration in American Whites: Systematic Review and Meta-analysisAmerican Journal of Ophthalmology, 2015
- Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysisThe Lancet. Global Health, 2014
- Baseline Predictors for One-Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular DegenerationOphthalmology, 2012
- The Age-related Eye Disease Study 2 (AREDS2)Ophthalmology, 2012
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2011
- The Natural History and Prognosis of Neovascular Age-Related Macular Degeneration: A Systematic Review of the Literature and Meta-analysisOphthalmology, 2008
- The Amsler chart is of doubtful value in retinal screening for early laser therapy of subretinal membranes. The West London SurveyEye, 2004
- Validity and Interpretation of Amsler Grid ReportsAmerican Journal of Ophthalmology, 1993
- Earliest Symptoms Caused by Neovascular Membranes in the MaculaAmerican Journal of Ophthalmology, 1986